AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinical safety rating
cautionComprehensive clinical and safety monograph for AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE (AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE).
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
| Metabolism | Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle. |
| Excretion | Renal: >95% as amino acids and metabolites; negligible biliary/fecal. |
| Half-life | Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels. |
| Protein binding | Minimal (<10%) for most amino acids; not significantly protein-bound. |
| Volume of Distribution | Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate metabolic effects (minutes to 1 hour) as amino acids enter circulation. |
| Duration of Action | Intravenous: 2-4 hours post-infusion for plasma amino acid elevation; clinical note: intermittent infusion leads to peaks and troughs. |
| Molecular Weight | Average 146.14 (range for essential amino acids; histidine MW 155.15) |
Intravenous infusion: 500 mL of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 30 mL/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 mL/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy. |
| Pediatric use | Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response. |
| Geriatric use | Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure. |
| 1st trimester | No adequate human studies; use only if clearly needed. Essential amino acids with histidine are generally considered safe in pregnancy when required for maternal nutrition. |
| 2nd trimester | No adequate human studies; use only if clearly needed. Essential amino acids are critical for fetal development. |
| 3rd trimester | No adequate human studies; use only if clearly needed. Essential amino acids are important for fetal growth. |
Clinical note
Comprehensive clinical and safety monograph for AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE (AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE).
| Placental transfer | Essential amino acids are actively transported across the placenta; histidine is known to cross. Exogenous amino acids likely cross similarly. |
| Breastfeeding | No data on excretion in human milk. Essential amino acids are normal components of breast milk; supplementation unlikely to cause harm, but use caution and monitor infant. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes. |
| Fetal Monitoring | Monitor maternal serum electrolytes, acid-base balance, blood glucose, and liver/renal function. Fetal growth monitoring via ultrasound if long-term use. |
| Fertility Effects | No known adverse effects on fertility. Correction of maternal malnutrition may improve fertility outcomes. |
■ FDA Black Box Warning
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
| Serious Effects |
AnuriaSevere hepatic failureInborn errors of amino acid metabolism
| Precautions | Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment, Use with caution in patients with metabolic acidosis or fluid overload, May cause gastrointestinal intolerance; adjust rate of administration |
| Food/Dietary | No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function. |
| Clinical Pearls | Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line. |
| Patient Advice | This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein. · It is given intravenously; report any burning, pain, or swelling at the IV site. · Your blood may be monitored for ammonia and electrolyte levels during treatment. · Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions. |
Loading safety data…